|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Current Management of the Short Bowel Syndrome显示文摘 | Jon S. Thompson Rebecca Weseman Fedja A. Rochling David F. Mercer | 2011 | Surgical Clinics of North America2011，，3： | 1 |
| 2 | Acetaminophem toxicity in an urban country hospital显示文摘 | Sehiodt FV Rochling FA Casey DL | 2003 | N Engl Jmed2003，349，16： | 1 |
| 3 | Potency,continence and complications in 3477 consecutive radical retropubic prostatectomies显示文摘 | Kundu S D Rochl K A Eggener S E | 2004 | J Urol2004，1721，： | 1 |
| 4 | Current management of the short-bowel syndrome 显示文摘 | Thompson JS Weseman R Rochling FA | 2011 | Surg Clin North AM2011，91，3： | 1 |
| 5 | Current management of short bowel syndrome 显示文摘 | Thompson JS Rochling FA Weseman RA | 2012 | Curr Probl Surg2012，49，2： | 1 |
| 6 | Current man- agement of short bowel syndrome 显示文摘 | Thompson JS Rochling FA Weseman RA | 2012 | C urr Probl Surg2012，49，2： | 1 |
| 7 | Current management of short bowel syndrome显示文摘 | Thompson JS Rochling FA Weseman RA | 2012 | Curr Probl Surg2012，49，2： | 1 |
| 8 | A 25-year experience with postresection short-bowel syndrome secondary to radiation therapy显示文摘 | Boland E Thompson J Rochling F | 2010 | Am J Surg2010，200，6： | 1 |
| 9 | Acetaminophen toxicity in an urban country hospital显示文摘 | Schiodt FV Rochling FA Casey DL | 1997 | N Engl J Med1997，337，16： | 1 |
| 10 | Radiation therapy increases the risk of hepatobiliary complications in short bowel syndrome显示文摘 | Thompson JS Weseman R Rochling F | | 0，，04： | 1 |
| 11 | Impact of psychosocial comorbidities on clinical outcomes after liver transplantation: Stratification of a high-risk population显示文摘BACKGROUND Liver transplantation is the accepted standard of care for end-stage liver disease due to a variety of etiologies including decompensated cirrhosis, fulminant hepatic failure, and primary hepatic malignancy. There are currently over 13000 candidates on the liver transplant waiting list emphasizing the importance of rigorous patient selection. There are few studies regarding the impact of additional psychosocial barriers to liver transplant including financial hardship, lack of caregiver support, polysubstance abuse, and issues with medical noncompliance. We hypothesized that patients with certain psychosocial comorbidities experienced worse outcomes after liver transplantation. AIM To assess the impact of certain pre-transplant psychosocial comorbidities on outcomes after liver transplantation. METHODS A retrospective analysis was performed on all adult patients from 2012-2016. Psychosocial comorbidities including documented medical non-compliance, polysubstance abuse, financial issues, and lack of caregiver support were collected. The primary outcome assessed post-transplantation was survival. Secondary outcomes measured included graft failure, episodes of acute rejection, psychiatric decompensation, number of readmissions, presence of infection, recidivism for alcohol and other substances, and documented caregiver support failure.RESULTS For the primary outcome, there were no differences in survival. Patients with a history of psychiatric disease had a higher incidence of psychiatric decompensation after liver transplantation (19% vs 10%, P = 0.013). Treatment of psychiatric disorders resulted in a reduction of the incidence of psychiatric decompensation (21% vs 11%, P = 0.022). Patients with a history of polysubstance abuse in the transplant evaluation had a higher incidence of substance abuse after transplantation (5.8% vs 1.2%, P = 0.05). In this cohort, 15 patients (3.8%) were found to have medical compliance issues in the transplant evaluation. Of these specific patients, 13.3% were found to have substance abuse after transplantation as opposed to 1.3% in patients without documented compliance issues (P = 0.03). CONCLUSION Patients with certain psychosocial comorbidities had worse outcomes following liver transplantation. Further prospective and multi-center studies are warranted to properly determine guidelines for liver transplantation regarding this highrisk population. | Neil Bhogal Amaninder Dhaliwal Elizabeth Lyden Fedja Rochling Marco Olivera-Martinez | 2019 | World Journal of Hepatology2019，11，8： | 0 |
| 12 | 坚实底盘上的轻型结构显示文摘一辆豪华轿车的整个车身底板仅重5kg-这是Rochling Automotive公司当前创下了新纪录。基于一种被称作“Softlofting”的工艺,使得Seeberlite结构材料在此发挥了作用。 | Rochling Automotive | 2009 | 汽车制造业2009，，B04： | 0 |
| 13 | Impact of sarcopenia on mortality in patients undergoing liver retransplantation显示文摘BACKGROUND Sarcopenia,which is a loss of skeletal muscle mass,has been reported to increase post-transplant mortality and morbidity in patients undergoing the first liver transplant.Cross-sectional imaging modalities typically determine sarcopenia in patients with cirrhosis by measuring core abdominal musculatures.However,there is limited evidence for sarcopenia related outcomes in patients undergoing liver re-transplantation(re-OLT).AIM To evaluate the risk of mortality in patients with pre-existing sarcopenia following liver re-OLT.METHODS This is a retrospective study of all adult patients who had undergone a liver re-OLT at the University of Nebraska Medical Center from January 1,2007 to January 1,2017.We divided patients into sarcopenia and no sarcopenia groups.“TeraRecon AquariusNet 4.4.12.194”software was used to evaluate computed tomography or magnetic resonance imaging of the patients done within one year prior to their re-OLT,to calculate the Psoas muscle area at L3-L4 intervertebral disc.We defined cutoffs for sarcopenia as<1561 mm2 for males and<1464 mm2 for females.The primary outcome was to compare 90 d,one,and 5-year survival rates.We also compared complications after re-OLT,length of stay,and readmission within 30 d.Survival analysis was performed with Kaplan-Meier survival analysis.Continuous variables were evaluated with Wilcoxon rank-sum tests.Categorical variables were evaluated with Fisher’s exact tests.RESULTS Fifty-seven patients were included,32 males:25 females,median age 50 years.Two patients were excluded due to incomplete information.Overall,47%(26)of patients who underwent re-OLT had sarcopenia.Females were found to have significantly more sarcopenia than males(73%vs 17%,P<0.001).Median model for end stage liver disease at re-OLT was 28 in both sarcopenia and no sarcopenia groups.Patients in the no sarcopenia group had a trend of longer median time between the first and second transplant(36.5 mo vs 16.7 mo).Biological markers,outcome parameters,and survival at 90 d,1 and 5 years,were similar between the two groups.Sarcopenia in re-OLT at our center was noted to be twice as common(47%)as historically reported in patients undergoing primary liver transplantation.CONCLUSION Overall survival and outcome parameters were no different in those with and without the evidence of sarcopenia after re-OLT. | Amaninder Dhaliwal Diana Larson Molly Hiat Lyudmila M Muinov William L Harrison Harlan Sayles Tomoki Sempokuya Marco A Olivera Fedja A Rochling Timothy M McCashland | 2020 | World Journal of Hepatology2020，12，10： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员